Haemonetics (NYSE: HAE) and Cytori Therapeutics (NASDAQ:CYTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Haemonetics and Cytori Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Haemonetics $886.12 million 3.44 -$26.26 million $0.08 720.97
Cytori Therapeutics $4.66 million 1.96 -$22.04 million ($0.90) -0.29

Cytori Therapeutics has lower revenue, but higher earnings than Haemonetics. Cytori Therapeutics is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.


This table compares Haemonetics and Cytori Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Haemonetics 0.50% 11.16% 6.79%
Cytori Therapeutics -367.33% -228.21% -69.19%

Volatility & Risk

Haemonetics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Cytori Therapeutics has a beta of 2.75, meaning that its share price is 175% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Haemonetics and Cytori Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Haemonetics 0 2 3 0 2.60
Cytori Therapeutics 0 1 1 0 2.50

Haemonetics presently has a consensus price target of $51.20, suggesting a potential downside of 11.22%. Cytori Therapeutics has a consensus price target of $3.65, suggesting a potential upside of 1,303.85%. Given Cytori Therapeutics’ higher possible upside, analysts plainly believe Cytori Therapeutics is more favorable than Haemonetics.

Institutional and Insider Ownership

7.4% of Cytori Therapeutics shares are held by institutional investors. 1.2% of Haemonetics shares are held by company insiders. Comparatively, 1.9% of Cytori Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


Haemonetics beats Cytori Therapeutics on 8 of the 13 factors compared between the two stocks.

About Haemonetics

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

About Cytori Therapeutics

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.